Endothelial cells and astrocytes: a concerto en duo in ischemic pathophysiology.
Endothelial cells and astrocytes: a concerto en duo in ischemic pathophysiology.
复制标题
DOI：
10.1155/2012/176287
复制
发表时间：
2012
影响因子：
--
通讯作者：
Badaut J
中科院分区：
文献类型：
--
作者：
Berezowski V;Fukuda AM;Cecchelli R;Badaut J
神经血管/胶质血管单位最近在脑缺血研究中获得了越来越多的关注，特别是关于星形胶质细胞和内皮细胞中发生的细胞和分子变化。在本文中，我们总结了最近的知识，这些变化与水肿的形成，与基底膜的相互作用，血脑屏障功能障碍。我们还回顾了星形胶质细胞和内皮细胞与重组组织型纤溶酶原激活剂的关系，重组组织型纤溶酶原激活剂是唯一一种FDA批准的卒中后溶栓药物。但其治疗时间窗窄，临床副作用严重。最后，我们为未来的缺血药物开发提供了替代治疗靶点，例如过氧化物酶体增殖物激活受体和c-Jun N-末端激酶途径的抑制剂。在神经保护药物的开发中，靶向神经血管单位以保护血脑屏障，而不是传统的以神经元为中心的方法，可能会改善卒中后的临床结局。
The neurovascular/gliovascular unit has recently gained increased attention in cerebral ischemic research, especially regarding the cellular and molecular changes that occur in astrocytes and endothelial cells. In this paper we summarize the recent knowledge of these changes in association with edema formation, interactions with the basal lamina, and blood-brain barrier dysfunctions. We also review the involvement of astrocytes and endothelial cells with recombinant tissue plasminogen activator, which is the only FDA-approved thrombolytic drug after stroke. However, it has a narrow therapeutic time window and serious clinical side effects. Lastly, we provide alternative therapeutic targets for future ischemia drug developments such as peroxisome proliferator- activated receptors and inhibitors of the c-Jun N-terminal kinase pathway. Targeting the neurovascular unit to protect the blood-brain barrier instead of a classical neuron-centric approach in the development of neuroprotective drugs may result in improved clinical outcomes after stroke.